The effects of statin and fibrate on lowering small dense LDL‐cholesterol in hyperlipidemic patients with type 2 diabetes

• Tokuno Anna

  First Department of Internal Medicine, Showa University School of Medicine.

• Hirano Tsutomu

  First Department of Internal Medicine, Showa University School of Medicine.

• Hayashi Toshiyuki

  First Department of Internal Medicine, Showa University School of Medicine.

• Mori Yusaku

  First Department of Internal Medicine, Showa University School of Medicine.

• Yamamoto Takeshi

  First Department of Internal Medicine, Showa University School of Medicine.

• Nagashima Masaharu

  First Department of Internal Medicine, Showa University School of Medicine.

• Shiraishi Yuji

  First Department of Internal Medicine, Showa University School of Medicine.

• Ito Yasuki

  Denka Seiken, Co.

• Adachi Mitsuru

  First Department of Internal Medicine, Showa University School of Medicine.

書誌事項

タイトル別名

• The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes

抄録

Aim: Small dense (sd)-low-density lipoprotein (LDL) is a potent atherogenic lipoprotein. The overall atherogenicity of this lipoprotein can be precisely assessed by quantifying sd-LDL rather than by measuring the LDL size. We studied the effects of representative lipid-lowering agents (statin and fibrate) on sd-LDL-cholesterol (C) in patients with type 2 diabetes. <BR>Methods: Sd-LDL-C was measured by the precipitation method established by Hirano and Ito. Large buoyant (lb)-LDL-C was calculated by subtracting sd-LDL-C from LDL-C. Type 2 diabetes patients (n=72) were administered lipid-lowering agents for three months: patients with hypercholesterolemia received 1 mg of pitavastatin and those with hypertriglyceridemia received 100 mg of micronized fenofibrate. <BR>Results: Pitavastatin reduced LDL-C by 25% and reduced TG by 8%. The statin decreased sd-LDL-C by 26%, and lb-LDL-C by 22%. Fenofibrate reduced TG by 38% and increased HDL-C by 14%. The fibrate decreased sd-LDL-C by 23% without changing LDL-C. The pitavastatin-induced reduction of sd-LDL-C was significantly correlated with the reduction of LDL-C and apo B, whereas the fenofibrate-induced reduction of sd-LDL-C was correlated with the reduction of TG. <BR>Conclusion: Both statin and fibrate reduce the potency of atherogenic sd-LDL particles, but via different mechanisms: the former decreases total-LDL including sd-LDL, while the latter decreases sd-LDL specifically.

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ

  Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ 14 (3), 128-132, 2007

  一般社団法人 日本動脈硬化学会

キーワード

• Small dense LDL-cholesterol
• Type 2 diabetes
• Pitavastatin
• Fenofibrate

詳細情報

• CRID: 1390282679407837440
• NII論文ID: 130004444204
• NII論文ID: 10022606594
• NII書誌ID: AA11018976
• DOI: 10.5551/jat.14.128
• COI: 1:CAS:528:DC%2BD2sXot1Krsrc%3D
• ISSN: 18803873
• ISSN: 13403478
• ISSN: http://id.crossref.org/issn/13403478
• Web Site: https://www.jstage.jst.go.jp/article/jat/14/3/14_3_128/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2008114813
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可